Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy National Research stock

Learn how to easily invest in National Research stock.

National Research Corp is a health information services business based in the US. National Research shares (NRC) are listed on the NASDAQ and all prices are listed in US Dollars. National Research employs 511 staff and has a trailing 12-month revenue of around $151.8 million.

How to buy shares in National Research

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – NRC – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

National Research stock price (NASDAQ: NRC)

Use our graph to track the performance of NRC stocks over time.

National Research shares at a glance

Information last updated 2022-10-02.
Latest market close$40.64
52-week range$30.56 - $51.28
50-day moving average $36.89
200-day moving average $37.70
Wall St. target priceN/A
PE ratio 28.0282
Dividend yield $0.72 (1.78%)
Earnings per share (TTM) $1.42

Buy National Research shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy National Research stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

National Research price performance over time

Historical closes compared with the close of $40.64 from 2022-10-03

1 week (2022-09-23) 3.57%
1 month (2022-08-31) N/A
3 months (2022-07-01) 4.58%
6 months (2022-03-31) N/A
1 year (2021-10-04) -3.58%
2 years (2020-10-02) -20.80%
3 years (2019-10-04) 59.63
5 years (2017-10-04) 7.37%

Is National Research stock undervalued or overvalued?

Valuing National Research stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of National Research's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

National Research's P/E ratio

National Research's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, National Research shares trade at around 28x recent earnings.

That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).

National Research's EBITDA

National Research's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $54.7 million.

The EBITDA is a measure of a National Research's overall financial performance and is widely used to measure a its profitability.

National Research financials

Revenue TTM $151.8 million
Operating margin TTM 32.49%
Gross profit TTM $95.6 million
Return on assets TTM 21.4%
Return on equity TTM 49.87%
Profit margin 23.82%
Book value $2.77
Market capitalisation $985.7 million

TTM: trailing 12 months

National Research share dividends


Dividend payout ratio: 59.2% of net profits

Recently National Research has paid out, on average, around 59.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.45% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), National Research shareholders could enjoy a 2.45% return on their shares, in the form of dividend payments. In National Research's case, that would currently equate to about $0.72 per share.

National Research's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

National Research's most recent dividend payout was on 14 October 2022. The latest dividend was paid out to all shareholders who bought their shares by 29 September 2022 (the "ex-dividend date").

National Research share price volatility

Over the last 12 months, National Research's shares have ranged in value from as little as $30.5599 up to $51.2756. A popular way to gauge a stock's volatility is its "beta".

NRC.US volatility(beta: 0.68)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while National Research's is 0.6772. This would suggest that National Research's shares are less volatile than average (for this exchange).

National Research overview

National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations.

Frequently asked questions

What percentage of National Research is owned by insiders or institutions?
Currently 43.318% of National Research shares are held by insiders and 47.097% by institutions.
How many people work for National Research?
Latest data suggests 511 work at National Research.
When does the fiscal year end for National Research?
National Research's fiscal year ends in December.
Where is National Research based?
National Research's address is: 1245 Q Street, Lincoln, NE, United States, 68508
What is National Research's ISIN number?
National Research's international securities identification number is: US6373722023
What is National Research's CUSIP number?
National Research's Committee on Uniform Securities Identification Procedures number is: 637372103

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site